Study supports OmniActive’s sustained release caffeine’s nootropic effects
Data published in Current Research in Behavioral Science also indicated that the sustained release caffeine ingredient helped maintain improved alertness and mood in subjects for extended periods of time.
“Alertness and mood are important nootropic benefits that consumers are seeking as part of their self-care regime,” wrote researchers from OmniActive Health Technologies and ClinSync Clinical Research Pvt. Ltd (India). “Thus, our proprietary sustained-release caffeine formulation may provide a beneficial alternative to repeated caffeine dosing to maintain energy levels through the day with fewer deleterious side-effects associated with “caffeine crash” phenomenon.
“Our study also provides important insights on plasma caffeine concentrations and its effects on behavioral performance.”
Xtenergy
OmniActive unveiled its sustained release caffeine ingredient at SupplySide West in 2019 and is positioned for the energy and as a nootropic. The ingredient is derived from green coffee bean, and is developed using a solvent-free process and the spray melt technology that involves coating caffeine granules, according to OmniActive.
“Not all energy is the same and the needs of the market are evolving,” said Kimberly Smith, CMO of OmniActive.
“Xtenergy is a unique, branded solution that delivers benefits in multiple categories, from consumers who want sustained energy and nootropic benefits to power through the day to more niche segments, like esports and gaming, where the competitive advantage of clean energy is key
“The health benefits of Xtenergy along with this new piece of science will help our customers further differentiate and standout in an increasingly crowded marketplace.”
Study details
The new study measured the bioavailability of Xtenergy vs. immediate release caffeine. The researchers also addressed the ingredient’s nootropic benefits, such as alertness and mood.
Twenty-four healthy men with an average age of 32.7 were recruited and assigned to receive either a single 200 mg dose of Xtenergy or 99% Immediate Release (IR) caffeine. The researchers measured plasma caffeine levels and the Caffeine-Visual Analogue Scale (VAS) was used to measure feelings of relaxation, alertness, jitteriness, tension, and overall mood.
The results showed that the IR caffeine resulted in a prompt increase in absorption that peaked within the first hour but was immediately followed by a sharp decline up until 24 hours.
However, the sustained release caffeine peaked around four hours, representing a 325% increase versus the IR caffeine.
In addition, it remained in the blood approximately 21% longer than IR caffeine, said the researchers.
The VAS data indicated that Xtenergy was also associated with feelings of being more alert, less tired, better overall mood, less jittery and less tense, compared to the IR caffeine.
“Since the nature of the caffeine formulation can directly influence the rate and extent of absorption of caffeine and its subsequent physiological effects, OmniActive formulated Xtenergy to release caffeine in an extended, sustained format over a period of 6-8 hours,” explained Deshanie Rai, VP, Global Scientific & Regulatory Affairs for OmniActive. “This allows Xtenergy to deliver on key nootropic benefits that consumers want through the day.”
Source: Current Research in Behavioral Sciences
Volume 2, 100036, doi: 10.1016/j.crbeha.2021.100036
“Pharmacokinetic profile of a novel sustained-release caffeine with extended benefits on alertness and mood: A randomized, double-blind, single-dose, active-controlled, crossover study”
Authors: A. Morde et al.
